Ocular Therapeutix, Inc. ( OCUL ) NASDAQ Global Market

Cena: 8.29 ( 1.97% )

Aktualizacja 06-23 21:17
NASDAQ Global Market
Branża: Biotechnology
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Zdrowie
Branża: Biotechnology
Zatrudnienie: 267
Giełda: NASDAQ Global Market
Ilość akcji w obrocie: 89%
Ilość akcji: 110 219 000
Debiut giełdowy: 2014-07-25
WWW: https://www.ocutx.com
CEO: Dr. Pravin U. Dugel M.D.
Adres: 24 Crosby Drive
Siedziba: 01730 Bedford
ISIN: US67576A1007
Opis firmy:

Ocular Therapeutix, Inc., firma biofarmaceutyczna, koncentruje się na sformułowaniu, rozwoju i komercjalizacji terapii chorób i warunków oka przy użyciu technologii preparatu opartego na hydrożelu Bioresorbable. Rynki firmy Resure Seale, urządzenie okulistyczne, aby zapobiec wyciekom ran podczas nacięć rogówki po operacji zaćmy; i dextenza, dexametazon wkładka okulistyczna w celu leczenia pooperacyjnego zapalenia oka i bólu po operacji okulistycznej, a także alergiczne zapalenie spojówek. Rozwija się również OTX-TKI, axitynib do wewnątrzgałkowego implantu, który znajduje się w badaniach klinicznych fazy 1 w leczeniu zwyrodnienia plamki związanej z mokrem i innymi chorobami siatkówki; OTX-TIC, implant wewnątrzczaszkowy travoprost, który jest w badaniach klinicznych fazy 2 w leczeniu jaskry otwartego kątowego lub nadciśnienia oka; OTX-CSI, wstawka wewnątrzczaszkowa cyklosporyna, która zakończyła badania kliniczne fazy 2 w leczeniu choroby suchej oka; i OTX-ded, wkładka wewnątrzczaszkowa deksametazonowa, która jest w badaniach klinicznych fazy 2 w celu krótkoterminowego leczenia objawów choroby suchej oka. Firma prowadzi strategiczną współpracę z Regeneron Pharmaceuticals, Inc. (Regeneron) w celu opracowywania i komercjalizacji produktów z wykorzystaniem hydrożelu o długotrwałym uwalnianiu firmy w połączeniu z dużymi cząsteczkowymi związkami ukierunkowanymi na VEGF w regeneron w celu leczenia chorób siatkówki; oraz Affed Therapeutics ograniczony do rozwoju i komercjalizacji Dextenza i OTX-TIC, a także współpracy odkrywczej z biosciencesami mozaikowymi w celu zidentyfikowania nowych celów i środków terapeutycznych w leczeniu zwyrodnienia plamki platformy związanej z suchym wiekiem (DMAD). Ocular Therapeutix, Inc. został włączony w 2006 roku i ma siedzibę w Bedford, Massachusetts.

Wskaźniki finansowe
Kapitalizacja (USD) 1 320 597 000
Aktywa: 490 369 000
Cena: 8.29
Wskaźnik Altman Z-Score: 4.3
Stabilny (niskie ryzyko bankructwa)
Dywidenda: 0
P/E: -7.5
Ilość akcji w obrocie: 89%
Średni wolumen: 1 979 637
Ilość akcji 159 300 000
Wskaźniki finansowe
Przychody TTM 61 382 999
Zobowiązania: 138 348 000
Przedział 52 tyg.: 5.785 - 11.775
Piotroski F-Score: 3
Słaby (niska jakość finansowa)
EPS: -1.1
P/E branży: 26.1
Beta: 1.256
Raport okresowy: 2025-08-04
WWW: https://www.ocutx.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Dr. Jeffrey S. Heier M.D. Chief Scientific Officer 86 162 1961
Mr. Donald Notman Jr. Chief Financial Officer 679 770 0
Mr. Philip C. Strassburger Esq. General Counsel 282 613 1960
Dr. Pravin U. Dugel M.D. Executive Chairman, President & Chief Executive Officer 0 1964
Mr. William H. Ransone II Vice President of Global Sales & Marketing 0 0
Mr. Steve Meyers Chief Commercial Officer 0 0
Mr. William S. Slattery Jr. Vice President of Investor Relations 0 0
Dr. Karen-Leigh Edwards M.B.A., Ph.D. Chief Operations Officer 0 0
Dr. Peter K. Jarrett Ph.D. Chief Technology Officer 0 1957
Ms. Tracy Smith Vice President of Human Resources 0 0
Wiadomości dla Ocular Therapeutix, Inc.
Tytuł Treść Źródło Aktualizacja Link
Ocular Therapeutix™ to Participate in Upcoming Investor Conferences BEDFORD, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor conferences in the second half of May 2025. globenewswire.com 2025-05-14 11:00:00 Czytaj oryginał (ang.)
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.24 per share a year ago. zacks.com 2025-05-05 13:15:39 Czytaj oryginał (ang.)
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to its newly appointed Executive Director, Payer Access, Thomas J. Cella, and one other newly hired non-executive employee. The awards were made as inducements material to the individual's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). globenewswire.com 2025-04-11 20:30:00 Czytaj oryginał (ang.)
Ocular Therapeutix™ to Participate in Two Investor Conferences in April BEDFORD, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that the Company will participate in two investor conferences in April: globenewswire.com 2025-03-31 11:00:00 Czytaj oryginał (ang.)
Why Ocular Therapeutix Was Bumping Higher This Week The market was seeing Ocular Therapeutix (OCUL -6.52%) very positively this week, and that sunny view pushed the company's stock higher. fool.com 2025-03-14 10:36:28 Czytaj oryginał (ang.)
Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside Needham initiated coverage on Ocular Therapeutix Inc OCUL, noting the company's lead asset, Axpaxli, an investigational axitinib-based intravitreal implant for wet age-related macular degeneration (wet AMD). benzinga.com 2025-03-11 16:49:42 Czytaj oryginał (ang.)
Ocular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster Potential Ocular Therapeutix focuses on Axpaxli, a long-acting wet AMD therapy administered every 6-12 months. Dextenza currently drives revenues, but Axpaxli is expected to unlock long-term growth. Ocular has two important Phase 3 trials (SOL-1 and SOL-R), which are key catalysts this year, with data expected by early 2026. seekingalpha.com 2025-03-06 13:15:03 Czytaj oryginał (ang.)
Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.28 per share a year ago. zacks.com 2025-03-03 11:15:26 Czytaj oryginał (ang.)
Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025 BEDFORD, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Monday, March 3, 2025, at 8:00 AM ET to discuss recent business progress and financial results for the fourth quarter and full year ended December 31, 2024. globenewswire.com 2025-02-24 09:00:00 Czytaj oryginał (ang.)
Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting BEDFORD, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced upcoming presentations at the Angiogenesis, Exudation, and Degeneration 2025 virtual meeting on February 8, 2025. globenewswire.com 2025-02-03 09:00:00 Czytaj oryginał (ang.)
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., Jan. 17, 2025 (GLOBE NEWSWIRE) --  Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to one newly hired employee. The awards were made as inducements material to the individual's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). globenewswire.com 2025-01-17 09:00:00 Czytaj oryginał (ang.)
Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR 311 subjects enrolled across various stages of loading and randomization in SOL-R, Ocular's second registrational trial of AXPAXLI™ in wet AMD, as of January 10, 2024 globenewswire.com 2025-01-14 09:00:00 Czytaj oryginał (ang.)
Ocular Is Now Thoroughly Derisked Ocular Therapeutics' OTX-TKI implant offers a cost-effective, long-lasting alternative to gene therapies for wet AMD, showing superior duration and comparable efficacy to Regeneron's Eylea. Recent FDA approval for trial modifications and positive phase 1 results in NPDR patients enhance OTX-TKI's potential, with phase 3 data expected by Q4 2025. Financially, OCUL is strong with a $1.34bn market cap and $427mn cash, ensuring a runway of 8-9 quarters despite high R&D expenses. seekingalpha.com 2024-12-30 14:16:51 Czytaj oryginał (ang.)
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it has agreed to grant inducement awards to one newly hired employee. The awards were made as inducements material to the individual's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). globenewswire.com 2024-12-13 09:00:00 Czytaj oryginał (ang.)
Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference BEDFORD, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference to be held January 13-16, 2025 in San Francisco, CA. globenewswire.com 2024-12-10 09:30:00 Czytaj oryginał (ang.)
Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1 SOL-1 is the first registrational trial for AXPAXLI™ in wet AMD Topline clinical data from SOL-1 expected in Q4 2025 Active clinical trial sites enrolling patients directly into second registrational trial, SOL-R, while additional sites continue to be activated BEDFORD, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that more than 300 patients have been randomized in the SOL-1 Phase 3 trial for AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI), and the trial is expected to close randomization this week. globenewswire.com 2024-12-02 09:30:00 Czytaj oryginał (ang.)
Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences BEDFORD, Mass. , Nov. 26, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced participation in several investor and scientific conferences being held in December. globenewswire.com 2024-11-26 09:30:00 Czytaj oryginał (ang.)
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.51 per share a year ago. zacks.com 2024-11-14 11:41:08 Czytaj oryginał (ang.)
Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV BEDFORD, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced upcoming presentations at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV. globenewswire.com 2024-11-13 09:30:00 Czytaj oryginał (ang.)
Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024 BEDFORD, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it plans to host a conference call and webcast on Thursday, November 14, 2024, at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2024. globenewswire.com 2024-11-06 09:30:00 Czytaj oryginał (ang.)
Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD SOL-1 is now expected to be enrolled and fully randomized by year-end 2024 Topline clinical data from SOL-1 are now expected in Q4 2025 BEDFORD, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced accelerated timelines for the SOL-1 Phase 3 registrational clinical trial of AXPAXLI in wet age-related macular degeneration (wet AMD). globenewswire.com 2024-10-15 11:30:00 Czytaj oryginał (ang.)
Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last? Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. zacks.com 2024-10-14 15:00:19 Czytaj oryginał (ang.)
Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To Investors In my previous article, I rated Ocular as a “Hold” based on concerns regarding Axpaxli's path to market. The SOL-1 and SOL-R Phase III trials are designed to assess Axpaxli's safety, efficacy, and potential market disruption in wet-AMD treatment. OCUL's Elutyx drug delivery platform offers sustained long-term effects, making it a valuable asset beyond current retina-focused applications. seekingalpha.com 2024-10-11 09:50:26 Czytaj oryginał (ang.)
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it has agreed to grant inducement awards to its newly appointed Chief Legal Officer, Todd D.C. Anderman. The awards were made as inducements material to Mr. Anderman's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). globenewswire.com 2024-10-09 20:05:00 Czytaj oryginał (ang.)
Ocular Therapeutix™ to Present at October Ophthalmology Meetings BEDFORD, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced participation in multiple panels and presentations across three ophthalmology meetings in Chicago, Illinois during October 2024. globenewswire.com 2024-10-09 11:30:00 Czytaj oryginał (ang.)
Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024 BEDFORD, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it will participate in the UBS Virtual Opthalmology Day 2024: globenewswire.com 2024-09-25 11:30:00 Czytaj oryginał (ang.)
Ocular Therapeutix™ to Present at September Retina Meetings BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced multiple presentations across four retina meetings being held in Portugal and Spain in September 2024. globenewswire.com 2024-09-05 11:30:00 Czytaj oryginał (ang.)
Ocular Therapeutix™ to Present at Two Investor Conferences in September BEDFORD, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it will participate in two investor conferences in September: globenewswire.com 2024-09-04 11:30:00 Czytaj oryginał (ang.)
Ocular Therapeutix, Inc. (OCUL) Q2 2024 Earnings Call Transcript Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Q2 2024 Earnings Conference Call August 7, 2024 8:00 AM ET Company Participants Bill Slattery - VP, IR Pravin Dugel - Executive Chairman, President, CEO Conference Call Participants Tazeen Ahmad - Bank of America Merrill Lynch Biren Amin - Piper Sandler Tara Bancroft - TD Cowen Colleen Kusy - Baird Kelly Shi - Jefferies Sean McCutcheon - Raymond James Yi Chen - H.C. Wainwright & Co. Operator Good morning, and welcome to the Ocular Therapeutix second-quarter 2024 earnings conference call. seekingalpha.com 2024-08-09 16:53:09 Czytaj oryginał (ang.)
Wall Street Analysts See an 85.43% Upside in Ocular Therapeutix (OCUL): Can the Stock Really Move This High? The consensus price target hints at an 85.4% upside potential for Ocular Therapeutix (OCUL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com 2024-08-09 14:55:34 Czytaj oryginał (ang.)
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it has agreed to grant inducement awards to four newly hired employees. The awards were made as inducements material to each individual's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). globenewswire.com 2024-08-09 11:30:00 Czytaj oryginał (ang.)
Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.27 per share a year ago. zacks.com 2024-08-07 13:46:07 Czytaj oryginał (ang.)